JP2006502231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502231A5 JP2006502231A5 JP2004546786A JP2004546786A JP2006502231A5 JP 2006502231 A5 JP2006502231 A5 JP 2006502231A5 JP 2004546786 A JP2004546786 A JP 2004546786A JP 2004546786 A JP2004546786 A JP 2004546786A JP 2006502231 A5 JP2006502231 A5 JP 2006502231A5
- Authority
- JP
- Japan
- Prior art keywords
- hemoglobin
- use according
- solution
- polymerized
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001554 Hemoglobins Human genes 0.000 claims 25
- 108010054147 Hemoglobins Proteins 0.000 claims 25
- 229920000642 polymer Polymers 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 206010047139 Vasoconstriction Diseases 0.000 claims 2
- 230000004872 arterial blood pressure Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 239000000356 contaminant Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000025033 vasoconstriction Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41593502P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/031377 WO2004037279A1 (en) | 2002-10-03 | 2003-10-03 | Method for treating patients with massive blood loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502231A JP2006502231A (ja) | 2006-01-19 |
| JP2006502231A5 true JP2006502231A5 (enExample) | 2006-10-05 |
Family
ID=32176456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004546786A Pending JP2006502231A (ja) | 2002-10-03 | 2003-10-03 | 大量失血を被っている患者の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7291592B2 (enExample) |
| EP (1) | EP1553968A4 (enExample) |
| JP (1) | JP2006502231A (enExample) |
| CN (1) | CN1703235A (enExample) |
| AU (1) | AU2003272827B2 (enExample) |
| CA (1) | CA2499459A1 (enExample) |
| MX (1) | MXPA05003340A (enExample) |
| NO (1) | NO20051390L (enExample) |
| RU (1) | RU2325924C2 (enExample) |
| WO (1) | WO2004037279A1 (enExample) |
| ZA (1) | ZA200502307B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049707A1 (en) * | 2003-08-29 | 2005-03-03 | Ferree Bret A. | Cemented artificial disc replacements |
| US7747315B2 (en) * | 2002-01-15 | 2010-06-29 | Board Of Regents, The University Of Texas System | Methods and compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| EP1978802A2 (en) * | 2006-01-24 | 2008-10-15 | Northfield Laboratories, Inc. | Polymerized hemoglobin media and its use in isolation and transplantation of islet cells |
| WO2008009635A2 (en) * | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
| RU2361608C1 (ru) * | 2008-03-18 | 2009-07-20 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" | Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты) |
| RU2452519C1 (ru) * | 2011-03-25 | 2012-06-10 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ компенсации глобулярного объема крови и иммуномодулирующего воздействия при трансплантации |
| EP3655019A4 (en) | 2017-07-18 | 2021-04-21 | Virtech Bio, Inc. | BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464814A (en) | 1986-06-20 | 1995-11-07 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US4826811A (en) | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5194590A (en) * | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5854209A (en) | 1995-03-23 | 1998-12-29 | Biopure Corporation | Method for oxygenating tissue having reduced red blood cell flow |
| US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
| US5955581A (en) | 1986-11-10 | 1999-09-21 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| AU705225B2 (en) * | 1995-03-23 | 1999-05-20 | Biopure Corporation | Stable polymerized hemoglobin blood substitute |
| US20020065211A1 (en) | 1995-03-23 | 2002-05-30 | Biopure Corporation | Increasing function of organs having reduced red blood cell flow |
| US5895810A (en) | 1995-03-23 | 1999-04-20 | Biopure Corporation | Stable polymerized hemoglobin and use thereof |
| US6150507A (en) | 1995-03-23 | 2000-11-21 | Biopure Corporation | Method for producing a purified hemoglobin product |
| US6288027B1 (en) | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| US5691452A (en) | 1995-03-23 | 1997-11-25 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US6271351B1 (en) | 1995-03-23 | 2001-08-07 | Biopure Corporation | Method for preserving a hemoglobin blood substitute |
| US5691453A (en) | 1995-06-07 | 1997-11-25 | Biopure Corporation | Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC |
| SK134398A3 (en) * | 1996-03-28 | 2001-01-18 | Northfield Lab | Aqueous solution of the pyridoxylated polymerized hemoglobin and method for preparing the same |
| US5890852A (en) * | 1998-03-17 | 1999-04-06 | Emerson Electric Company | Thread cutting die and method of manufacturing same |
-
2003
- 2003-10-03 AU AU2003272827A patent/AU2003272827B2/en not_active Expired - Fee Related
- 2003-10-03 RU RU2005113240/14A patent/RU2325924C2/ru not_active IP Right Cessation
- 2003-10-03 CN CNA2003801009126A patent/CN1703235A/zh active Pending
- 2003-10-03 CA CA002499459A patent/CA2499459A1/en not_active Abandoned
- 2003-10-03 EP EP03755029A patent/EP1553968A4/en not_active Withdrawn
- 2003-10-03 JP JP2004546786A patent/JP2006502231A/ja active Pending
- 2003-10-03 US US10/678,927 patent/US7291592B2/en not_active Expired - Fee Related
- 2003-10-03 MX MXPA05003340A patent/MXPA05003340A/es active IP Right Grant
- 2003-10-03 WO PCT/US2003/031377 patent/WO2004037279A1/en not_active Ceased
-
2005
- 2005-03-16 NO NO20051390A patent/NO20051390L/no not_active Application Discontinuation
- 2005-03-18 ZA ZA2005/02307A patent/ZA200502307B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bagshaw et al. | Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury | |
| Brophy et al. | AN-69 membrane reactions are pH-dependent and preventable | |
| Leblanc et al. | Lithium poisoning treated by high-performance continuous arteriovenous and venovenous hemodiafiltration | |
| Bayliss | Dialysis in the poisoned patient | |
| Rapeport et al. | The use of “ketofol”(ketamine-propofol admixture) infusion in conjunction with regional anaesthesia | |
| Chan et al. | Hong Kong’s experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1) | |
| Movilli et al. | Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy | |
| Xie et al. | Continuous veno venous hemofiltration in treatment of acute necrotizing pancreatitis | |
| Matsuda et al. | Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure | |
| Pezzi et al. | The use of coupled plasma filtration adsorption in traumatic rhabdomyolysis | |
| RU2005113240A (ru) | Способ лечения пациентов с массивной потерей крови | |
| US20070275086A1 (en) | Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy | |
| Huang et al. | Delayed near-fatal anaphylactic reaction induced by the F10-HPS polysulphone haemodialyser | |
| Buturović‐Ponikvar et al. | Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: short heparin‐free hemodialysis helps to attenuate citrate load | |
| Li et al. | The roller coaster of lamotrigine levels: Successful treatment of massive lamotrigine overdose with continuous veno-venous hemodiafiltration and rifampin | |
| Lu et al. | Acute massive gentamicin intoxication in a patient with end-stage renal disease | |
| Chan et al. | Ammonia detoxification by continuous venovenous haemofiltration in an infant with urea cycle defect | |
| Low et al. | Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity | |
| Chaignon et al. | Hemodynamic effects of hemodialysis and hemofiltration | |
| Trakarnvanich et al. | The efficacy of single-needle versus double-needle hemodialysis in chronic renal failure | |
| Pierratos et al. | Nocturnal hemodialysis: An update | |
| RU2530759C1 (ru) | Способ детоксикации организма | |
| RU2406539C2 (ru) | Способ лечения хронической почечной недостаточности | |
| Miyakawa et al. | Dialysis | |
| HK40103606A (en) | Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response |